Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations

• Drug: Treatment A
  
  Viagra® 100 mg tablet, administered with water single dose
• Drug: Blood samples for the analysis of sildenafil in plasma
  
  Blood samples for the analysis of sildenafil in plasma
• Drug: Treatment B
  
  Sildenafil 100 mg CT administered with water single dose
• Other: Blood samples for the analysis of sildenafil in plasma
  
  Blood samples for the analysis of sildenafil in plasma
• Drug: Treatment C
  
  Sildenafil 100 mg CT administered without water single dose

• Active Comparator: Treatment A
  
  Viagra® 100 mg tablet, administered with water
  Interventions:
  

  • Drug: Treatment A
  • Drug: Blood samples for the analysis of sildenafil in plasma
• Active Comparator: Treatment B
  
  Sildenafil 100 mg CT administered with water
  Interventions:
  

  • Drug: Treatment B
  • Other: Blood samples for the analysis of sildenafil in plasma
• Active Comparator: Treatment C
  
  Sildenafil 100 mg CT administered without water
  Interventions:
  

  • Drug: Treatment C
  • Other: Blood samples for the analysis of sildenafil in plasma

Inclusion Criteria:

• Only healthy male volunteers in the 18-40 age range will be included.
• At the selection visit allowed normal range for vital signs will be: Blood pressure (with the subject sitting down) 90-130mm Hg systolic and 60-90
• The volunteers' health condition will be determined from their complete clinical history by doctors at the clinical research site and lab test results by certified clinical laboratories mm Hg diastolic, heart rate 55-100 bpm , respiratory rate 14-20 respirations per minute.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at Screening.
• Treatment with a PDE-5 inhibitor within the 4 days preceding the first dose of study medication
• History of hypersensitivity to sildenafil citrate or any components of its formulations